Coherus Biosciences

Coherus Oncology (formerly Coherus Biosciences) is a fully integrated commercial-stage biopharmaceutical company focused on developing and commercializing next-generation immuno-oncology therapies. Its approved product LOQTORZI (toripalimab-tpzi) is a PD-1 inhibitor for hard-to-treat cancers. The company's pipeline includes multiple clinical-stage candidates targeting the tumor microenvironment, including CCR8 and IL-27 pathways, with the goal of extending patient survival across tumor types.